COVID-19 Threatens Pharma’s Global Supply Chain. What Next?
In an increasingly global pharmaceutical supply chain, the COVID-19 outbreak has posed an existential challenge to an industry working across national borders. The virus has already shut down some production in China and affected exports of some active pharmaceutical ingredients from India. With access strained, cost inevitably increases.
A few key questions:
- How much of that cost can be passed along and how much must producers assume?
- Should the industry rewrite its supply chain script going forward?
- What policies should regulators have in hand to protect drug supplies for patients?
- Is it time for governments to subsidize API production in their own countries to insure constant supplies or can the market sort this out?
In this Fierce Pharma webcast, Leon Wyszkowski, President, Commercial Operations, and other experts discussed how to navigate the current global supply chain challenges.